Epithalon 10mg dosage

The strongest published case for epithalon's 10mg dose comes from a single 2002 Russian clinical trial in elderly adults, where that amount administered over twelve days produced measurable increases in melatonin secretion and cortisol regulation. It is not the only dose tested in research, but it is the one that appears most frequently in the small body of human literature — which, to be clear, is neither large nor conducted under current regulatory standards.

Epithalon: A Pineal-Derived Tetrapeptide Built to Mimic AEDG

Epithalon is a four-amino-acid synthetic peptide (alanine-glutamic acid-aspartic acid-glycine, abbreviated AEDG) originally derived from epithalamin, a natural peptide extract of the bovine pineal gland. The compound was developed in the 1980s by Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology, part of a broader program investigating how pineal gland secretions influence aging and circadian regulation. At 390.35 Da, it is one of the smallest peptides with active longevity-focused research behind it.

The compound was synthesized to isolate the active sequence from epithalamin, which is a complex mixture. Unlike Semax or Selank — peptides designed to mimic endogenous neuropeptides — epithalon was designed to mimic a specific fragment believed responsible for the pineal gland's role in biological aging. Its small size makes it relatively stable in solution and straightforward to synthesize, though its short half-life (discussed below) requires repeated administration in most experimental protocols.

How Epithalon Activates Telomerase and Alters Gene Expression in Senescent Cells

Epithalon's proposed primary mechanism is telomerase activation. Telomerase is the enzyme encoded by the TERT gene that adds repetitive TTAGGG sequences to the ends of chromosomes, effectively extending telomeres — the protective DNA-protein caps that shorten with each cell division in most somatic cells. In normal adult tissues, telomerase is suppressed after development. When telomeres become critically short, cells enter senescence (permanent growth arrest) or apoptosis. In cell culture studies from Khavinson's group, epithalon treatment increased telomerase activity in human somatic fibroblasts and lymphocytes, leading to measurable telomere elongation over multiple passages.

The mechanism by which a tetrapeptide crosses the cell membrane and influences nuclear gene expression is not fully characterized. Proposed pathways include receptor-mediated internalization or direct interaction with transcription factors, though no specific receptor has been cloned or validated. The compound also appears to modulate gene expression beyond telomerase: microarray studies in rodent cardiac and brain tissue showed altered transcription of genes involved in circadian regulation, oxidative stress response, and apoptosis. These studies were conducted in rats treated subcutaneously over weeks to months, not single-dose exposures.

In vitro work also suggests epithalon influences pineal gland output. In cultured rat pinealocytes, the peptide increased melatonin synthesis and secretion, consistent with its hypothesized role as a pineal gland regulator. Whether this effect translates meaningfully to whole-organism melatonin rhythms in humans is less certain.

Twelve Days in Elderly Humans, Years in Rodent Cancer Models: What the Studies Actually Show

The human evidence base for epithalon is thin. The most frequently cited human trial is a 2002 open-label study in 14 elderly subjects (ages 60–74) conducted by Khavinson's group. Participants received 10mg of epithalon via intramuscular injection daily for 12 days. The study reported increases in nighttime melatonin levels, normalized cortisol rhythms, and subjective improvements in sleep quality. No placebo control was included, and follow-up ended at 30 days. A separate 2003 publication from the same group described six-month follow-up in 266 elderly individuals given epithalon (dose and schedule unspecified), reporting reductions in mortality and cancer incidence compared to historical controls. These studies were not conducted under GCP standards and have not been independently replicated outside Russia.

The rodent literature is more extensive but still originates largely from a single research group. In long-term studies, epithalon administration (typically 0.1–1.0 µg/kg subcutaneously, 5 days per week for months) extended median lifespan in outbred rats by 12–25%, reduced spontaneous tumor incidence, and delayed age-related changes in estrous cyclicity and immune function. In carcinogen-induced tumor models, epithalon pretreatment reduced tumor multiplicity and delayed onset in mammary, colon, and lung tissues. The effect appears to be partially mediated by restored melatonin rhythms and enhanced antioxidant enzyme activity, though telomerase modulation was not directly measured in most cancer studies.

In cell culture, treatment with epithalon (1–100 µM) extended replicative lifespan in human fibroblasts by 20–40%, with concurrent increases in telomerase activity measured by TRAP assay. These results have been reproduced within Khavinson's laboratory but not by independent labs outside Eastern Europe. The lack of independent validation remains a significant gap in the evidence base.

10mg Daily for 12 Days: The Dosing Protocol That Appears Most Often in Human Literature

The 10mg dose appears in the 2002 human trial as a once-daily intramuscular injection given for 12 consecutive days. This is the most specific human dose-and-schedule combination published in peer-reviewed literature. For research purposes only, this protocol has been informally replicated in longevity research communities, though no controlled follow-up data exists outside the original trial. Some rodent studies used far lower doses by body weight (0.1–1.0 µg/kg), which would translate to micrograms in a 70kg human if scaled allometrically — orders of magnitude below 10mg. The discrepancy likely reflects differences in administration route, peptide stability, and dose-response curves that are poorly characterized.

Half-life data in humans is not published. In rodent pharmacokinetics, subcutaneous epithalon shows rapid clearance, with plasma concentrations peaking within 30 minutes and declining to baseline by 4 hours. This short half-life may explain the daily dosing schedule in human trials. The peptide is hydrophilic and unlikely to accumulate in adipose tissue. Whether repeated daily administration leads to tissue accumulation or receptor desensitization has not been studied.

Administration routes in published research include subcutaneous and intramuscular injection. No oral bioavailability data exists, and like most unmodified peptides, epithalon is unlikely to survive gastric digestion intact. Stability in reconstituted solution has not been formally characterized, though anecdotal reports suggest refrigerated peptide solutions remain active for weeks. Lyophilized powder appears stable at -20°C for at least one year based on indirect evidence from research supplier data sheets.

No formal drug interaction studies exist. Theoretical concerns include interactions with immunosuppressants (epithalon may enhance immune function in aging models) and potentially with cancer therapies, given its effects on telomerase and cell proliferation. The peptide has not been tested alongside chemotherapy or radiation in controlled settings.

FAQ

Q: Why is 10mg the most common dose in human research if rodent studies use micrograms?

The 10mg dose comes from a single 1990s Russian clinical trial and has not been formally optimized. Rodent studies used far lower doses scaled by body weight, but differences in half-life, receptor density, and administration route make direct scaling unreliable. No dose-ranging study in humans exists, so the 10mg figure represents historical precedent rather than pharmacologically derived optimization.

Q: Does epithalon actually extend telomeres in human cells outside the lab?

Cell culture studies from Khavinson's group showed telomere elongation in human fibroblasts treated with epithalon over multiple passages, measured by terminal restriction fragment length assays. Whether this occurs in vivo in human tissue after systemic administration is unknown. No published study has measured telomere length in human subjects before and after epithalon treatment.

Q: How does epithalon compare to other telomerase activators like TA-65?

TA-65 is a small molecule derived from Astragalus membranaceus that activates telomerase through a different mechanism. It has been tested in small human trials with mixed results on telomere length and no consistent lifespan data in rodents. Epithalon's rodent lifespan data is stronger, but its human data is weaker and methodologically limited. No head-to-head comparison exists.

Q: Is the Russian clinical data on epithalon considered reliable by Western standards?

The trials conducted by Khavinson's group in the 1990s and 2000s were published in peer-reviewed journals but were not conducted under ICH-GCP standards. They lack placebo controls, independent oversight, and data transparency. The findings are plausible given the rodent data, but they do not meet the evidentiary bar required for regulatory approval in the US or EU.

Q: What happens after the 12-day cycle ends?

The 2002 trial followed subjects for 30 days post-treatment and reported sustained increases in melatonin output. Long-term follow-up data does not exist. Whether benefits persist, require repeated cycles, or fade after weeks is unknown. Some research protocols use repeated cycles (e.g., 10 days every six months), but this is not based on controlled human data.

---

Epithalon and related peptides are not approved for human use by the FDA or EMA. The information above is provided for educational and research purposes only. This content does not constitute medical advice, and no therapeutic claims are made. Consult a licensed healthcare provider before using any research compound.